Xin Lang Cai Jing·2025-12-08 03:22Company Overview - Beijing Springli Medical Co., Ltd. is primarily engaged in the research, production, and sales of implantable orthopedic medical devices, with a focus on joint prosthetics and spinal implants [2] - The company was established on February 12, 1998, and went public on December 30, 2021 [2] - Main products include hip, knee, shoulder, and elbow joint prosthetics, as well as a full range of spinal fixation systems [2] Financial Performance - For the period from January to September 2025, the company achieved a revenue of 756 million yuan, representing a year-on-year growth of 48.75% [2] - The net profit attributable to the parent company for the same period was 192 million yuan, showing a significant year-on-year increase of 213.21% [2] Shareholder Information - As of September 30, 2025, the number of shareholders increased to 6,164, up by 4.12% from the previous period [2] - The average number of circulating shares per person decreased by 3.95% to 46,906 shares [2] - The company has distributed a total of 359 million yuan in dividends since its A-share listing, with 309 million yuan distributed over the past three years [3] Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited is the fourth-largest circulating shareholder, holding 2.9585 million shares as a new shareholder [3] - China Europe Economic Growth Selected Mixed A (020876) is the fifth-largest circulating shareholder, holding 2.8326 million shares, also as a new shareholder [3] - Ping An Low Carbon Economy Mixed A (009878) is the eighth-largest circulating shareholder, holding 2.1 million shares, which is a decrease of 1.67 million shares from the previous period [3]